glofitamab
roche
['lymsm', 'car-t', 'glofitamab', 'dlbcl']
 - glofitamab in r/r dlbcl
- over 150 pts, 1/3 car-t failure
- 8-12 cycles
- approx 50% orr, 40% crr
- no effect of prior car-t
- low rates serious crs &amp; v low icans
v impressive data. long term fu of crs show possible cures. #eha2022 #eha22 #lymsm 
Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Past chair of UK Hodgkin and T-cell study groups.